The Future of Peptide Therapeutics: FDA Pipeline and Approved Compounds
Over 100 peptide therapeutics are currently FDA-approved and hundreds more are in clinical pipelines. This article surveys the regulatory landscape, current approval categories, and what the emerging pipeline suggests about the next decade.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Peptide-based therapeutics have transitioned from a niche pharmacological category to one of the fastest-growing segments of the drug development pipeline. Over 100 peptide drugs have received FDA approval, and estimates from industry analyses suggest more than 400 peptide candidates are currently in active clinical development worldwide.
Research reference only. This article covers regulatory history and pipeline data as a reference for understanding the therapeutic context of peptide compounds. It does not constitute investment advice or guidance for human use.
The Scale of Approved Peptide Therapeutics
The FDA has approved peptide drugs across virtually every major therapeutic category. Approved compounds span a wide range of molecular sizes and delivery mechanisms:
Metabolic and endocrine: Insulin and insulin analogues (the original peptide drugs), glucagon-like peptide-1 receptor agonists (semaglutide, liraglutide, dulaglutide), pramlintide (amylin analogue), and teduglutide (GLP-2 analogue for short bowel syndrome)
Cardiovascular: Bivalirudin (thrombin inhibitor), eptifibatide (GPIIb/IIIa antagonist), nesiritide (BNP analogue), carperitide
Oncology: Leuprolide, goserelin, triptorelin (GnRH analogues for hormone-sensitive cancers), octreotide and lanreotide (somatostatin analogues for carcinoid/acromegaly), romidepsin (HDAC inhibitor), carfilzomib
Dermatology: Afamelanotide (Scenesse, MC1R agonist approved 2019 for erythropoietic protoporphyria), omiganan (Phase 3 for rosacea)
Neurology: Ziconotide (N-type calcium channel blocker from cone snail toxin), difelikefalin (peripheral kappa opioid receptor agonist for pruritus)
Immunology and infectious disease: Thymalfasin/Zadaxin (Thymosin Alpha-1, approved outside US), enfuvirtide (HIV fusion inhibitor), icatibant (bradykinin antagonist for hereditary angioedema)
The Peptide Therapeutics Foundation estimated in 2022 that the global peptide therapeutics market exceeded $50 billion annually, with GLP-1 class drugs now representing the largest single category by revenue.
Advantages of Peptide Drugs in Development
The continued growth of the peptide pipeline reflects structural advantages over small molecules and biologics:
Receptor selectivity: Peptides can be designed to engage specific receptor subtypes with high precision, reducing off-target toxicity relative to many small molecules. The selectivity profile of ipamorelin versus other ghrelin mimetics is one example of this advantage being exploited in research design.
Defined mechanism: Unlike many natural product-derived drugs, synthetic peptides have predictable structure-activity relationships that allow systematic optimization.
Metabolic degradation products: Peptide catabolism typically produces amino acids rather than reactive toxic metabolites, which simplifies toxicology.
Manufacturing advances: Solid-phase peptide synthesis (SPPS) has become substantially more efficient since Merrifield's original 1963 method, enabling cost-competitive manufacturing of peptides up to ~50 amino acids.
Persistent Challenges
Oral bioavailability: The fundamental barrier to oral peptide delivery remains GI proteolysis and poor mucosal permeability. Oral semaglutide (Rybelsus) — requiring 300 mg of an absorption enhancer (SNAC) to deliver ~14 mg of active drug — illustrates both the progress made and the magnitude of the challenge.
Half-life: Unmodified peptides are cleared rapidly by proteases and renal filtration. Chemical strategies (PEGylation, fatty acid conjugation, cyclization, D-amino acid substitution) have substantially extended half-lives for many approved drugs but add development complexity.
Manufacturing cost: At scale, peptide synthesis remains more expensive per gram than small molecule synthesis, particularly for longer sequences requiring protecting group chemistry.
Current FDA Pipeline: Key Categories
GLP-1 and Incretin Axis
The GLP-1 class is the most active area of peptide clinical development. Beyond approved semaglutide and tirzepatide, multiple candidates are in Phase 2/3:
- Retatrutide (LY3437943): Triple GLP-1/GIP/glucagon agonist, Phase 3 (SURMOUNT program). Phase 2 data (Jastreboff et al., NEJM, 2023) showed 24.2% weight loss at 48 weeks
- Orforglipron: Non-peptide GLP-1 agonist (oral small molecule) in Phase 3; not technically a peptide but competing in the same indication
- Cagrilintide: Amylin analogue in Phase 3 combination with semaglutide (CagriSema)
- Mazdutide: GLP-1/glucagon dual agonist in Phase 3 (China-based trial)
Cardiovascular and Renal
- Rilvegostomig: Not a peptide, but the CV peptide space includes several natriuretic peptide analogues in Phase 2
- Elamipretide (SS-31): Mitochondria-targeting peptide in Phase 2/3 for heart failure (MMPOWER-HF; primary endpoint not met but secondary endpoints positive)
Oncology
- Peptide-drug conjugates (PDCs) represent a fast-growing oncology category, attaching cytotoxic payloads to tumor-targeting peptides. Several PDCs are in Phase 2 for solid tumors
Dermatology and Rare Disease
- Afamelanotide (already approved) continues in Phase 3 expansion studies for vitiligo and other photodermatoses
- Setmelanotide: MC4R agonist approved for rare genetic obesity syndromes, under investigation for broader applications
Regulatory Pathways for Peptide Drugs
Standard NDA/BLA Review
Most synthetic peptides below ~40 amino acids qualify as small-molecule New Drug Applications (NDAs) rather than Biologics License Applications (BLAs). This distinction matters for development cost, generics pathway (Hatch-Waxman vs BPCIA), and interchangeability rules.
Breakthrough Therapy and Fast Track
The GLP-1 class has benefited from Breakthrough Therapy Designation, accelerating FDA review timelines for compounds with transformative early-phase data. Compounds addressing rare or life-threatening conditions with no adequate alternatives may qualify for:
- Orphan Drug Designation: 7 years of market exclusivity post-approval
- Fast Track Designation: Rolling review and more frequent FDA interaction
- Breakthrough Therapy Designation: Intensive FDA guidance throughout development
Typical Development Timeline
From initial synthesis to approval, peptide therapeutics average 10–15 years and $1–2 billion in development costs. Phase 3 failure rates for peptide drugs are approximately 40–50%, consistent with broader pharmaceutical development rates.
Research-to-Approval: The Gap for Investigated Compounds
Many compounds actively studied in research contexts — including BPC-157, TB-500, GHK-Cu, Epitalon, and others in this library — remain in preclinical or very early Phase 1 stages, if they have entered formal clinical development at all. The gap between preclinical promise and clinical approval is substantial, and most compounds do not complete the journey.
This does not diminish their value as research tools for understanding basic biology, but it is important context for interpreting preclinical literature. See the compound library for evidence tier ratings on individual compounds.
All content is for research reference purposes only. Not intended as medical advice or to guide human use.